HomeCompareTOS vs CL

TOS vs CL: Dividend Comparison 2026

TOS yields 8.14% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CL wins by $6.5K in total portfolio value· pulled ahead in Year 9
10 years
TOS
TOS
● Live price
8.14%
Share price
$24.57
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.3K
Annual income
$1,362.18
Full TOS calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — TOS vs CL

📍 CL pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTOSCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TOS + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TOS pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TOS
Annual income on $10K today (after 15% tax)
$691.90/yr
After 10yr DRIP, annual income (after tax)
$1,157.85/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, CL beats the other by $3,433.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TOS + CL for your $10,000?

TOS: 50%CL: 50%
100% CL50/50100% TOS
Portfolio after 10yr
$37.5K
Annual income
$3,382.07/yr
Blended yield
9.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

TOS
No analyst data
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TOS buys
0
CL buys
0
No recent congressional trades found for TOS or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTOSCL
Forward yield8.14%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$34.3K$40.8K
Annual income after 10y$1,362.18$5,401.96
Total dividends collected$10.9K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TOS vs CL ($10,000, DRIP)

YearTOS PortfolioTOS Income/yrCL PortfolioCL Income/yrGap
1$11,514$814.00$11,012$312.01+$502.00TOS
2$13,196$875.93$12,196$412.95+$1.0KTOS
3$15,058$938.20$13,599$549.66+$1.5KTOS
4$17,112$1,000.54$15,288$736.64+$1.8KTOS
5$19,373$1,062.68$17,353$995.28+$2.0KTOS
6$21,853$1,124.35$19,926$1,357.80+$1.9KTOS
7$24,568$1,185.34$23,194$1,873.82+$1.4KTOS
8$27,534$1,245.42$27,439$2,621.52+$95.00TOS
9← crossover$30,765$1,304.43$33,088$3,727.38$2.3KCL
10$34,281$1,362.18$40,806$5,401.96$6.5KCL

TOS vs CL: Complete Analysis 2026

TOSStock

TOS seeks total return by investing in US equity securities across all market caps. The fund may invest in equities, other ETFs (including affiliated funds), and derivatives such as options, swaps, futures, and structured notes. Selection combines bottom-up fundamental research on individual securities with top-down portfolio analysis. The fund also may employ hedging strategies using option contracts, swaps, and other derivatives, hedging specific securities or broader market exposures through indices or ETFs. Certain derivatives can have a leverage-like effect. The fund may also invest in cash, cash equivalents, or money market instruments, and may hold an affiliated ETF focused on capital appreciation and low volatility during downturns. As an actively managed ETF, the fund manager has full discretion to adjust the portfolio at any time.

Full TOS Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this TOS vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TOS vs SCHDTOS vs JEPITOS vs OTOS vs KOTOS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.